A Post-Marketing Surveillance Study of Formoterol (Foradil®)1 View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2002-03

AUTHORS

Lynda V. Wilton, Saad A. Shakir

ABSTRACT

Objective: At the time of marketing, experience of long-term use of prescription medicines in general clinical practice is limited. Postmarketing surveillance is particularly important at this time when medicines may be prescribed to large numbers of patients of all ages, for long-term use. Following marketing of formoterol (Foradil®) in the UK in 1996 we undertook a postmarketing surveillance study of formoterol use in general practice.Design: A non-interventional observational cohort study was conducted using the technique of prescription-event monitoring. Exposure data were obtained from prescription details; outcome data from questionnaires sent to general practitioners approximately 12 months after the first prescription was dispensed for individual patients. Incidence rates were calculated for reported events, reasons for stopping treatment and outcomes of pregnancy were determined.Results: Data were collected for 5777 patients aged 3 to 96 years, 65% of whom continued treatment for >12 months. Formoterol was prescribed ‘off label’, to 258 children, (4.5%) of the cohort. The most commonly reported events excluding those related to respiratory disease, were headache, tremor, palpitation, cramp and nausea/vomiting. These events were also among the more common reasons for stopping treatment and reported as suspected adverse drug reactions. 33 patients took formoterol during pregnancy. The cause of death was established for 186 of the 190 deaths (3% of cohort).Conclusions: Formoterol appears to have been well tolerated by the majority of patients in this study. The most frequently reported adverse events were those known to be associated with β2-agonists, although the frequency of nausea/vomiting was greater than given in Summary of Product Characteristics. More... »

PAGES

213-223

References to SciGraph publications

  • 1998-02. Formoterol in DRUGS
  • 1997-06. Treatment of asthma during pregnancy in REACTIONS WEEKLY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.2165/00002018-200225030-00006

    DOI

    http://dx.doi.org/10.2165/00002018-200225030-00006

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1020065968

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/11945116


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Public Health and Health Services", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adolescent", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adrenergic beta-Agonists", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged, 80 and over", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cause of Death", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Child", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Child, Preschool", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cohort Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "England", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Ethanolamines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Formoterol Fumarate", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Nausea", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pregnancy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pregnancy Outcome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Product Surveillance, Postmarketing", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Surveys and Questionnaires", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Vomiting", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Drug Safety Research Unit, Bursledon Hall, Blundell Lane, SO31 1AA, Bursledon, Southampton, UK", 
              "id": "http://www.grid.ac/institutes/grid.418589.9", 
              "name": [
                "Drug Safety Research Unit, Bursledon Hall, Blundell Lane, SO31 1AA, Bursledon, Southampton, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wilton", 
            "givenName": "Lynda V.", 
            "id": "sg:person.0720152771.39", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720152771.39"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Drug Safety Research Unit, Bursledon Hall, Blundell Lane, SO31 1AA, Bursledon, Southampton, UK", 
              "id": "http://www.grid.ac/institutes/grid.418589.9", 
              "name": [
                "Drug Safety Research Unit, Bursledon Hall, Blundell Lane, SO31 1AA, Bursledon, Southampton, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Shakir", 
            "givenName": "Saad A.", 
            "id": "sg:person.010623121577.43", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010623121577.43"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.2165/00003495-199855020-00016", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018055932", 
              "https://doi.org/10.2165/00003495-199855020-00016"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00128415-199706570-00002", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039600874", 
              "https://doi.org/10.2165/00128415-199706570-00002"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2002-03", 
        "datePublishedReg": "2002-03-01", 
        "description": "Objective: At the time of marketing, experience of long-term use of prescription medicines in general clinical practice is limited. Postmarketing surveillance is particularly important at this time when medicines may be prescribed to large numbers of patients of all ages, for long-term use. Following marketing of formoterol (Foradil\u00ae) in the UK in 1996 we undertook a postmarketing surveillance study of formoterol use in general practice.Design: A non-interventional observational cohort study was conducted using the technique of prescription-event monitoring. Exposure data were obtained from prescription details; outcome data from questionnaires sent to general practitioners approximately 12 months after the first prescription was dispensed for individual patients. Incidence rates were calculated for reported events, reasons for stopping treatment and outcomes of pregnancy were determined.Results: Data were collected for 5777 patients aged 3 to 96 years, 65% of whom continued treatment for >12 months. Formoterol was prescribed \u2018off label\u2019, to 258 children, (4.5%) of the cohort. The most commonly reported events excluding those related to respiratory disease, were headache, tremor, palpitation, cramp and nausea/vomiting. These events were also among the more common reasons for stopping treatment and reported as suspected adverse drug reactions. 33 patients took formoterol during pregnancy. The cause of death was established for 186 of the 190 deaths (3% of cohort).Conclusions: Formoterol appears to have been well tolerated by the majority of patients in this study. The most frequently reported adverse events were those known to be associated with \u03b22-agonists, although the frequency of nausea/vomiting was greater than given in Summary of Product Characteristics.", 
        "genre": "article", 
        "id": "sg:pub.10.2165/00002018-200225030-00006", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1096281", 
            "issn": [
              "0114-5916", 
              "1179-1942"
            ], 
            "name": "Drug Safety", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "3", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "25"
          }
        ], 
        "keywords": [
          "nausea/vomiting", 
          "long-term use", 
          "surveillance study", 
          "non-interventional observational cohort study", 
          "observational cohort study", 
          "outcome of pregnancy", 
          "majority of patients", 
          "marketing surveillance study", 
          "prescription-event monitoring", 
          "adverse drug reactions", 
          "general clinical practice", 
          "cause of death", 
          "formoterol use", 
          "cohort study", 
          "first prescription", 
          "adverse events", 
          "drug reactions", 
          "general practitioners", 
          "incidence rate", 
          "individual patients", 
          "respiratory disease", 
          "\u03b22 agonists", 
          "general practice", 
          "prescription details", 
          "outcome data", 
          "common reason", 
          "prescription medicines", 
          "formoterol", 
          "clinical practice", 
          "patients", 
          "time of marketing", 
          "exposure data", 
          "vomiting", 
          "pregnancy", 
          "treatment", 
          "reported events", 
          "months", 
          "death", 
          "medicine", 
          "palpitations", 
          "headache", 
          "cramps", 
          "cohort", 
          "Foradil", 
          "disease", 
          "study", 
          "tremor", 
          "events", 
          "age", 
          "outcomes", 
          "prescription", 
          "children", 
          "surveillance", 
          "cause", 
          "questionnaire", 
          "use", 
          "majority", 
          "years", 
          "data", 
          "practice", 
          "product characteristics", 
          "summary", 
          "reasons", 
          "practitioners", 
          "time", 
          "rate", 
          "large number", 
          "experience", 
          "monitoring", 
          "UK", 
          "frequency", 
          "number", 
          "characteristics", 
          "labels", 
          "reaction", 
          "technique", 
          "detail", 
          "marketing"
        ], 
        "name": "A Post-Marketing Surveillance Study of Formoterol (Foradil\u00ae)1", 
        "pagination": "213-223", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1020065968"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.2165/00002018-200225030-00006"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "11945116"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.2165/00002018-200225030-00006", 
          "https://app.dimensions.ai/details/publication/pub.1020065968"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:23", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_359.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.2165/00002018-200225030-00006"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00002018-200225030-00006'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00002018-200225030-00006'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00002018-200225030-00006'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00002018-200225030-00006'


     

    This table displays all metadata directly associated to this object as RDF triples.

    242 TRIPLES      21 PREDICATES      128 URIs      118 LITERALS      29 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.2165/00002018-200225030-00006 schema:about N00f7fd130b924f48a0d78df772f35f25
    2 N1401a7fbe57a42caa5e3134b86cf09a4
    3 N2a67afc6403e4f6aa53a3e52dce33cf2
    4 N30cf09df50724f26b71f49b966c1f4a0
    5 N4d49f3204bf046df87f4dc05f2b64e27
    6 N55ef53aa50464934883f2d9cfb9e4365
    7 N5e001413d4f44c24bb9bef257cd5a460
    8 N5ed2bd59a72b436599870de19fad3d5a
    9 N61226f72f2c94d0b9e1b02f539ba4a2a
    10 N6c68a2239e474a7bb8d4b09623d34ebc
    11 N7963d1f2a6d64752a1c880ca46866307
    12 Nbf5472929bcf4c04a7eef9d8ef33016a
    13 Nc43c198154fb49db846f13fcfcb38dbb
    14 Ncccffa1d650f4c7691545ac8357c761e
    15 Nce26239ee1984d198eace5ef3092e723
    16 Ndccbcf870a43497e97afc3c47550feba
    17 Ndfd7dbdeb48d462bb40c8ba3963dc0b1
    18 Ne4c917a567e249459aa6efd61344ba38
    19 Nead8377c44b9429e8a3952395538efc0
    20 Nf458bc9e6a5140228d7d483781e481e1
    21 Nfb242c6687ae43bc94a30abacf22b5e2
    22 Nfd7b8a74910b4909b5b788621ff18e11
    23 anzsrc-for:11
    24 anzsrc-for:1117
    25 schema:author Nfb34dd6cded2468a90c2ac7730834635
    26 schema:citation sg:pub.10.2165/00003495-199855020-00016
    27 sg:pub.10.2165/00128415-199706570-00002
    28 schema:datePublished 2002-03
    29 schema:datePublishedReg 2002-03-01
    30 schema:description Objective: At the time of marketing, experience of long-term use of prescription medicines in general clinical practice is limited. Postmarketing surveillance is particularly important at this time when medicines may be prescribed to large numbers of patients of all ages, for long-term use. Following marketing of formoterol (Foradil®) in the UK in 1996 we undertook a postmarketing surveillance study of formoterol use in general practice.Design: A non-interventional observational cohort study was conducted using the technique of prescription-event monitoring. Exposure data were obtained from prescription details; outcome data from questionnaires sent to general practitioners approximately 12 months after the first prescription was dispensed for individual patients. Incidence rates were calculated for reported events, reasons for stopping treatment and outcomes of pregnancy were determined.Results: Data were collected for 5777 patients aged 3 to 96 years, 65% of whom continued treatment for >12 months. Formoterol was prescribed ‘off label’, to 258 children, (4.5%) of the cohort. The most commonly reported events excluding those related to respiratory disease, were headache, tremor, palpitation, cramp and nausea/vomiting. These events were also among the more common reasons for stopping treatment and reported as suspected adverse drug reactions. 33 patients took formoterol during pregnancy. The cause of death was established for 186 of the 190 deaths (3% of cohort).Conclusions: Formoterol appears to have been well tolerated by the majority of patients in this study. The most frequently reported adverse events were those known to be associated with β2-agonists, although the frequency of nausea/vomiting was greater than given in Summary of Product Characteristics.
    31 schema:genre article
    32 schema:isAccessibleForFree false
    33 schema:isPartOf N4ec72b737b724bd298b5676781bf895b
    34 Ne82d449c722847f0be248defb919e846
    35 sg:journal.1096281
    36 schema:keywords Foradil
    37 UK
    38 adverse drug reactions
    39 adverse events
    40 age
    41 cause
    42 cause of death
    43 characteristics
    44 children
    45 clinical practice
    46 cohort
    47 cohort study
    48 common reason
    49 cramps
    50 data
    51 death
    52 detail
    53 disease
    54 drug reactions
    55 events
    56 experience
    57 exposure data
    58 first prescription
    59 formoterol
    60 formoterol use
    61 frequency
    62 general clinical practice
    63 general practice
    64 general practitioners
    65 headache
    66 incidence rate
    67 individual patients
    68 labels
    69 large number
    70 long-term use
    71 majority
    72 majority of patients
    73 marketing
    74 marketing surveillance study
    75 medicine
    76 monitoring
    77 months
    78 nausea/vomiting
    79 non-interventional observational cohort study
    80 number
    81 observational cohort study
    82 outcome data
    83 outcome of pregnancy
    84 outcomes
    85 palpitations
    86 patients
    87 practice
    88 practitioners
    89 pregnancy
    90 prescription
    91 prescription details
    92 prescription medicines
    93 prescription-event monitoring
    94 product characteristics
    95 questionnaire
    96 rate
    97 reaction
    98 reasons
    99 reported events
    100 respiratory disease
    101 study
    102 summary
    103 surveillance
    104 surveillance study
    105 technique
    106 time
    107 time of marketing
    108 treatment
    109 tremor
    110 use
    111 vomiting
    112 years
    113 β2 agonists
    114 schema:name A Post-Marketing Surveillance Study of Formoterol (Foradil®)1
    115 schema:pagination 213-223
    116 schema:productId N38925d48409b4f61bd396f3dd555fb3e
    117 N4addb057df8a4bcdaa22ece78c28f9a5
    118 N6931c78c9c0c46d59109b0360511a4cc
    119 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020065968
    120 https://doi.org/10.2165/00002018-200225030-00006
    121 schema:sdDatePublished 2022-12-01T06:23
    122 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    123 schema:sdPublisher Ncb94082fec5245e785897f54d8af5c31
    124 schema:url https://doi.org/10.2165/00002018-200225030-00006
    125 sgo:license sg:explorer/license/
    126 sgo:sdDataset articles
    127 rdf:type schema:ScholarlyArticle
    128 N00f7fd130b924f48a0d78df772f35f25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    129 schema:name Vomiting
    130 rdf:type schema:DefinedTerm
    131 N1401a7fbe57a42caa5e3134b86cf09a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Humans
    133 rdf:type schema:DefinedTerm
    134 N1ef9d993f58f4de6b70c3af511eea721 rdf:first sg:person.010623121577.43
    135 rdf:rest rdf:nil
    136 N2a67afc6403e4f6aa53a3e52dce33cf2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Cohort Studies
    138 rdf:type schema:DefinedTerm
    139 N30cf09df50724f26b71f49b966c1f4a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    140 schema:name Middle Aged
    141 rdf:type schema:DefinedTerm
    142 N38925d48409b4f61bd396f3dd555fb3e schema:name pubmed_id
    143 schema:value 11945116
    144 rdf:type schema:PropertyValue
    145 N4addb057df8a4bcdaa22ece78c28f9a5 schema:name dimensions_id
    146 schema:value pub.1020065968
    147 rdf:type schema:PropertyValue
    148 N4d49f3204bf046df87f4dc05f2b64e27 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    149 schema:name Female
    150 rdf:type schema:DefinedTerm
    151 N4ec72b737b724bd298b5676781bf895b schema:volumeNumber 25
    152 rdf:type schema:PublicationVolume
    153 N55ef53aa50464934883f2d9cfb9e4365 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    154 schema:name Nausea
    155 rdf:type schema:DefinedTerm
    156 N5e001413d4f44c24bb9bef257cd5a460 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    157 schema:name Adult
    158 rdf:type schema:DefinedTerm
    159 N5ed2bd59a72b436599870de19fad3d5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    160 schema:name Adrenergic beta-Agonists
    161 rdf:type schema:DefinedTerm
    162 N61226f72f2c94d0b9e1b02f539ba4a2a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    163 schema:name England
    164 rdf:type schema:DefinedTerm
    165 N6931c78c9c0c46d59109b0360511a4cc schema:name doi
    166 schema:value 10.2165/00002018-200225030-00006
    167 rdf:type schema:PropertyValue
    168 N6c68a2239e474a7bb8d4b09623d34ebc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    169 schema:name Child
    170 rdf:type schema:DefinedTerm
    171 N7963d1f2a6d64752a1c880ca46866307 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    172 schema:name Pregnancy
    173 rdf:type schema:DefinedTerm
    174 Nbf5472929bcf4c04a7eef9d8ef33016a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    175 schema:name Ethanolamines
    176 rdf:type schema:DefinedTerm
    177 Nc43c198154fb49db846f13fcfcb38dbb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    178 schema:name Pregnancy Outcome
    179 rdf:type schema:DefinedTerm
    180 Ncb94082fec5245e785897f54d8af5c31 schema:name Springer Nature - SN SciGraph project
    181 rdf:type schema:Organization
    182 Ncccffa1d650f4c7691545ac8357c761e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    183 schema:name Child, Preschool
    184 rdf:type schema:DefinedTerm
    185 Nce26239ee1984d198eace5ef3092e723 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    186 schema:name Male
    187 rdf:type schema:DefinedTerm
    188 Ndccbcf870a43497e97afc3c47550feba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    189 schema:name Surveys and Questionnaires
    190 rdf:type schema:DefinedTerm
    191 Ndfd7dbdeb48d462bb40c8ba3963dc0b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    192 schema:name Product Surveillance, Postmarketing
    193 rdf:type schema:DefinedTerm
    194 Ne4c917a567e249459aa6efd61344ba38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    195 schema:name Aged, 80 and over
    196 rdf:type schema:DefinedTerm
    197 Ne82d449c722847f0be248defb919e846 schema:issueNumber 3
    198 rdf:type schema:PublicationIssue
    199 Nead8377c44b9429e8a3952395538efc0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    200 schema:name Formoterol Fumarate
    201 rdf:type schema:DefinedTerm
    202 Nf458bc9e6a5140228d7d483781e481e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    203 schema:name Aged
    204 rdf:type schema:DefinedTerm
    205 Nfb242c6687ae43bc94a30abacf22b5e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    206 schema:name Cause of Death
    207 rdf:type schema:DefinedTerm
    208 Nfb34dd6cded2468a90c2ac7730834635 rdf:first sg:person.0720152771.39
    209 rdf:rest N1ef9d993f58f4de6b70c3af511eea721
    210 Nfd7b8a74910b4909b5b788621ff18e11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    211 schema:name Adolescent
    212 rdf:type schema:DefinedTerm
    213 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    214 schema:name Medical and Health Sciences
    215 rdf:type schema:DefinedTerm
    216 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
    217 schema:name Public Health and Health Services
    218 rdf:type schema:DefinedTerm
    219 sg:journal.1096281 schema:issn 0114-5916
    220 1179-1942
    221 schema:name Drug Safety
    222 schema:publisher Springer Nature
    223 rdf:type schema:Periodical
    224 sg:person.010623121577.43 schema:affiliation grid-institutes:grid.418589.9
    225 schema:familyName Shakir
    226 schema:givenName Saad A.
    227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010623121577.43
    228 rdf:type schema:Person
    229 sg:person.0720152771.39 schema:affiliation grid-institutes:grid.418589.9
    230 schema:familyName Wilton
    231 schema:givenName Lynda V.
    232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720152771.39
    233 rdf:type schema:Person
    234 sg:pub.10.2165/00003495-199855020-00016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018055932
    235 https://doi.org/10.2165/00003495-199855020-00016
    236 rdf:type schema:CreativeWork
    237 sg:pub.10.2165/00128415-199706570-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039600874
    238 https://doi.org/10.2165/00128415-199706570-00002
    239 rdf:type schema:CreativeWork
    240 grid-institutes:grid.418589.9 schema:alternateName Drug Safety Research Unit, Bursledon Hall, Blundell Lane, SO31 1AA, Bursledon, Southampton, UK
    241 schema:name Drug Safety Research Unit, Bursledon Hall, Blundell Lane, SO31 1AA, Bursledon, Southampton, UK
    242 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...